pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LEQEMBI · news · pharmadog
← back to LEQEMBI
News mentioning LEQEMBI
28
stories
10h
Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
biospace
1d
CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
biospace
1d
Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update
fiercebiotech
2d
CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
biospace
3d
AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option
fiercebiotech
3d
Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
fiercebiotech
3d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
9d
London biotech Oyster harvests $60M for tau-targeting brain drugs
biopharma dive
16d
Novartis ends BioArctic pact; Two VC firms raise inaugural funds
endpoints
16d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
16d
BioArctic left out in the cold as Novartis walks away from $800M neuro collab
fiercebiotech
22d
Biogen set up for growth even without M&A but CEO won’t rule it out
biospace
22d
Biogen notches 3rd straight quarter of growth thanks to newer products, Apellis
biospace
Oct 14, 26
Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
biopharma dive
Oct 8, 26
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 29, 26
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
Jul 29, 26
Leqembi records best quarter since launch as Biogen raises underlying guidance
endpoints
Jul 23, 26
Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales
endpoints
Jul 14, 26
Erasca's $550M offering; Summit sells an antibiotic
endpoints
Jul 14, 26
STAT+: Akero team, backed by Fairmount, launches new immunology company
stat
Jul 14, 26
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
biopharma dive
May 11, 26
STAT+: Medicare’s miss on Alzheimer’s drug spending
stat
May 11, 26
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
stat
May 11, 26
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
stat
May 8, 26
FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering
endpoints
May 8, 26
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive